Under the Paperwork Reduction Act of 1995, no persons are required to respond

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)
(Not for submission under 37 CFR 1.33)

Application Number		10822882				
Filing Date		2004-04-13				
First Named Inventor Richa		ard Simons				
Art Unit		2863				
Examiner Name Adity		a S. Bhat				
Attorney Docket Number		H0006930-07661161.1163101				

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>			Name of Pate of cited Docu	entee or Applicant ment	Releva	Columns,Lines int Passages or s Appear		
	1	5495722		1996-0	3-05	Manson et al.					
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add		_
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		_
Examiner Initial*	taminer Cite No Publication Number Kind Code: Date Name of Patentee or Application of cited Document			Releva	Columns,Lines int Passages or s Appear	where Releva	ani				
	1	20020198990		2002-1	2-26	Bradfield et al					
	2	20030195640		2003-1	0-16	Krocker et al.					
If you wisl	h to a	dd additional U.S. Publ	ished Ap	plication	citatio	n information p	olease click the Ad	d button			Ξ
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country	y Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns, where Relevant Passages or Rel Figures Appear		Ts
	1	2002044750	JP			2002-02-08					
	2	0848215	FP			1998-06-17					Г

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Richa		ichard Simons		
(Not for submission under 37 CFR 1.99)	Art Unit		2863		
(Not for Submission ander or or it is say	Examiner Name	Aditya S. Bhat			
	Attorney Docket Numb	er	H0006930-07661161.1163101		
NON	PATENT LITERATURE	DOCL	UMENTS Remove		

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),

10822882

2004-04-13

T5

Application Number

Filing Date

publisher, city and/or country where published.

Evaminer Cite

Initials\* No.

	1							
						A-1-1	_	_
If you wish	h to a	dd add	litional non-patent literature document citation information please click the A	idd b	outton	Add	J	
			EXAMINER SIGNATURE					
Examiner	Signa	ture	Date Consider	d b				

\*EXAMINE: Initial if reference considered, whether or not clastion is in conformance with MPEP 609. Draw line through a clation if not in conformance and not considered, includes copy of this form with next communication to applicant.

\*See first Code or (LISTO Patent Decomment a west LISTO GOV or MEPP 901 64. "Enter often that issued the document to the location recommend."

See Kind Codes of USPTO Patent Documents at <u>years USPTO.000</u>/or MPEP 901.04. Enter office that sessed the document, by the low-letter code (WIPO Standard ST.3). \*Tot suppress patent document, the includes not the year of the might of the Emporer must procede the sent number of the patent document. The patent document, and the patent document of the patent document of the patent document. The patent document is patent document. The patent document is patent document. The patent is patent as patent document.

	Application Number		10822882		
_	Filing Date		2004-04-13		
E T	First Named Inventor	Richa	ard Simons		
)	Art Unit		2863		
,	Examiner Name	Adity	a S. Bhat		
	Attorney Docket Number		H0006930-07661161.1163101		

## CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

INFORMATION DISCLOSUR STATEMENT BY APPLICAN (Not for submission under 37 CFR 1.9)

That each item of information contained in the information disclosure statement was first cited in any communication  $\overline{M}$  from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a
foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

## SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/brian n. tufte/	Date (YYYY-MM-DD)	2006-02-02
Name/Print	Brian N. Tuffe	Registration Number	38638

This collection of Information is required by 3T CFR. 187 and 1.98. This information is required to obtain or retain a benefit by the public which is to lie (and by the USFTO is porcess) an application. Confidentially is generated by \$1.9.5.C. 120 and 3T CFR. 11.4. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USFTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this from and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operatment of Commence, P. 0. Box 1440, Alexandria, V.S. 2231-1450. D NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 2231-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is SU U.S. C. (2)(2)(2) (2) famishing of the information solicide is voluntary, and (3) the principal purpuses for which the information is used by the U.S. Patient and Trademan Kolline is to process another examines your submission related to a patient application or patient. If you do not furnish the requested process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission, which may related the process and/or examines your submission, which may related the process and/or examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disease records.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S. C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, cuting an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make indemninations a partial individuals.
  - 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1-14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.